• Research & Development

  Opsumit awaiting approval as treatment for inoperable CTEPH

  Posted by Pulmonary Hypertension News Moderator on May 2, 2018 at 8:28 am

  Actelion Pharmaceuticals submitted a supplemental new drug application to the FDA seeking expanded approval for Opsumit (macitentan) as treatment for inoperable CTEPH.

  Read more about it here: “Actelion Seeks Expanded Approval for Opsumit as Treatment for Inoperable CTEPH”

  Do you require treatment for CTEPH? How have you managed it so far?

  Pulmonary Hypertension News Moderator replied 6 years ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply